News und Analysen
Sonova to accelerate expansion of direct consumer access in Chinese market with acquisition of leading network of clinics
Tavneos® (avacopan) recommended by England’s NICE for the treatment of AAV (GPA/MPA)
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) is pleased to announce that England’s National Institute for Health and Care Excellence (NICE) has recommended Tavneos® in combination with a
Sonova revises FY 2022/23 outlook due to subdued market and ongoing input cost challenge
Finalization of Vifor Pharma acquisition
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220801005796/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: First signs of increased M&A activity due to attractive valuations
Extension of the postponement of the settlement of Vifor Pharma tender offer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712006199/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Annual General Shareholders’ Meeting 2022: Sonova shareholders approve all motions of the Board of Directors
DGAP-News: BB BIOTECH AG: Disruptive technologies are changing an entire industry
Straumann Group to acquire PlusDental, a doctor-led clear-aligner treatment solutions provider in Europe
Financial year 2021/22: Sonova delivers solid results and significantly advances its growth strategy
Update on the timeline for Vifor Pharma tender offer
Regulatory News:
CSL Limited (ASX: CSL; USOTC:CSLLY) yesterday announced an update regarding the Vifor Pharma AG acquisition. CSL has previously advised that it expected to be in a position to
Update zum Zeitplan des öffentlichen Kaufangebots für Vifor Pharma
Regulatory News:
CSL Limited (ASX: CSL; USOTC:CSLLY) hat gestern ein Update bezüglich der Übernahme der Vifor Pharma AG veröffentlicht. CSL hat zuvor mitgeteilt, dass das Unternehmen die
Kapruvia® approved by European Commission for the treatment of moderate-to-severe pruritus in hemodialysis patients
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005801/en/
Vifor Fresenius Medical Care Renal Pharma (VFMCRP)
Straumann Group reports very strong first quarter
94th Vifor Pharma Group Annual General Meeting
Regulatory News:
At today’s 94th Annual General Meeting of Vifor Pharma Ltd., shareholders approved all proposed resolutions put forward by the Board of Directors. The Annual General Meeting was
94. Generalversammlung der Vifor Pharma Gruppe
Regulatory News:
An der heutigen 94. ordentlichen Generalversammlung der Vifor Pharma AG haben die Aktionäre alle Anträge des Verwaltungsrats genehmigt. Die Generalversammlung fand erneut
DGAP-Adhoc: BB Biotech AG publishes its interim report
DGAP-News: BB BIOTECH AG: Increased investment level balanced by established core holdings
DIAMOND trial: Veltassa® enables patients to achieve long-term potassium control and optimized RAASi therapy
Regulatory News:
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Vifor Pharma today announced full results from its phase-IIIb DIAMOND trial showing that Veltassa® allowed patients to achieve
Publication of definitive end result for Vifor Pharma tender offer
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220327005085/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Publication of provisional end result for Vifor Pharma tender offer: Participation rate of 94 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220322006149/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Publication of definitive Interim Result for Vifor Pharma tender offer: CSL Behring AG declares offer successful
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220307005938/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Publication of provisional interim result for Vifor Pharma tender offer: Participation rate of 74 percent
Regulatory News:
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220302006217/en/
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
CSL
Neue Behandlungsoption für Patienten mit SHPT – Rayaldee® in der Schweiz ab sofort verfügbar
Vifor Pharma Schweiz AG gab heute die Markteinführung des Calcifediol-Retardpräparats Rayaldee® in der Schweiz bekannt. Rayaldee® ist die erste und einzige in Europa zugelassene orale Therapie